New hope for elderly lymphoma patients: stronger chemo combo shows promise

NCT ID NCT05245656

First seen Apr 30, 2026 · Last updated May 14, 2026 · Updated 4 times

Summary

This study tests whether adding a third drug (cytarabine) to the standard two-drug chemo regimen can help older adults with mantle cell lymphoma live longer without their cancer growing. The trial enrolls 90 patients aged 70+ (or 60+ if not eligible for transplant) who have not yet been treated. Participants receive either the standard two-drug therapy or a rotating schedule of two and three drugs, and researchers track how long the cancer stays under control and what side effects occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Samsung Medical Center

    RECRUITING

    Seoul, Gangnam-Gu, 06351, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.